describe the outcome of EGFR inhibition as well as the differences between erlotinib and panitumumab’s mechanisms of action. EGFR- driven cancer cells can become resistant to tyrosine kinase inhibitors. Explain the two types of EGFR blockade acquired resistance and propose a subsequent treatment option.

describe the outcome of EGFR inhibition as well as the differences between erlotinib and panitumumab’s mechanisms of action. EGFR- driven cancer cells can become resistant to tyrosine kinase inhibitors. Explain the two types of EGFR blockade acquired resistance and propose a subsequent treatment option.

Biochemistry

6th Edition

ISBN:9781305577206

Author:Reginald H. Garrett, Charles M. Grisham

Publisher:Reginald H. Garrett, Charles M. Grisham

Chapter32: The Reception And Transmission Of Extracellular Information

Section: Chapter Questions

Problem 21P

See similar textbooks

Similar questions

Distinguish between What is known of CD105 (endoglin) as an hepatcellular carcinoma marker and it’s potential as a drug target. Discuss: - Is anything known about its biology? E.g does it have known ligands and normal functions? - if you were to target it would you just use it to get growth inhibiting compound into the new blood vessels or is CD105 required for neovascularization?
It has been shown that unusual activation of TGFb signaling pathway is associated with breast cancer development. Please provide the short overview of the experimental plan how you can study this effect.
In a breast cancer patient whose tumor cells express large amounts of estrogen receptors and are therefore very sensitive to estradiol, which of these drugs will be very effective in reducing plasma levels of estradiol and consequently the breast tumor growth? Group of answer choices Letrozole Paclitaxel Methotrexate Megestrol
What is ARD? Discuss the mechanism of ARD and its importance.
Suggest how treating cancers using monoclonalantibodies could cause fewer side-effects thantreating them using conventional anti-cancerdrugs or radiotherapy.
Give some abnormal conditions wherein the APTT is prolonged. Why is APTT employed in monitoring a patient who is on heparin therapy?
Describe the experimental rationale that allowed the lacrepressor to be isolated ?
Explain the relationship between the variable number of tandem repeats in the insulin promoter (Class I versus Class III VNTR) and genetic susceptibility to autoimmune diabetes.
In many breast cancers, ER (alpha) activation by estrogens is generally considered responsible for enhanced proliferation, whereas that is counteracted by the presence of ER (beta),which exerts an antiproliferative effect. Please devise a strategy targeting both receptors for the treatment of this disease.
Discuss the challenges to producing anticancer drugsthat counteract the effects of mutations in tumorsuppressor genes
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions If you wanted to measure the kinase activity of VEGFR-2, what are some of the conventional methods/assays you would use?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions How would you determine robustness of the assay and validate the assay?